WIfI-guided decision-making for critical limb ischemia — endovascular vs. bypass strategy and limb salvage trajectory
Critical limb ischemia (CLI), now more precisely termed chronic limb-threatening ischemia (CLTI), is the end-stage manifestation of peripheral artery disease in which blood flow is insufficient to sustain resting tissue metabolism. Untreated, one-year major amputation rates approach 20–25%. The Society for Vascular Surgery WIfI classification was developed to move beyond ischemia alone and stratify true amputation risk and revascularization benefit using three independent, additive domains.
Peripheral artery disease (PAD) spans a spectrum from asymptomatic disease through intermittent claudication to CLTI. CLTI is defined clinically by the presence of ischemic rest pain, non-healing ulceration, or gangrene in a limb with objectively confirmed arterial insufficiency — typically ankle-brachial index (ABI) <0.4, ankle pressure <50-70 mmHg, toe pressure <30-50 mmHg, or absent pedal Doppler waveforms.
Unlike claudication, CLTI represents a limb- and life-threatening state: the annual mortality of CLTI patients rivals many cancers, reflecting the systemic burden of atherosclerosis, diabetes, and renal disease that so often coexist. The central clinical question is not simply "is there ischemia" but "will this specific wound, on this specific foot, with this specific degree of ischemia and infection, heal without a revascularization procedure" — a question ischemia severity alone cannot answer.
Wound (W0–W3): graded by depth and extent of tissue loss, from no wound (W0) through minor ulceration not requiring extensive reconstruction (W1-W2) to extensive deep ulceration or gangrene involving forefoot/midfoot structures (W3).
Ischemia (I0–I3): graded primarily by ankle-brachial index, ankle systolic pressure, toe pressure, or transcutaneous oxygen tension (TcPO2). I0 reflects near-normal perfusion (ABI ≥0.8, toe pressure ≥60 mmHg); I3 reflects severe ischemia (ABI ≤0.39, toe pressure <30 mmHg) incompatible with spontaneous wound healing.
foot Infection (fI0–fI3): graded using Infectious Diseases Society of America (IDSA) criteria, from no infection (fI0) through mild local cellulitis (fI1), deeper or more extensive infection (fI2), to infection with systemic inflammatory response (fI3, sepsis) — often requiring urgent debridement or drainage before, or in parallel with, revascularization.
Each domain is scored independently 0-3 and the three scores are combined via a validated matrix into a single Clinical Stage (1 = very low risk, 4 = high risk) that predicts both 1-year amputation risk and the magnitude of benefit expected from revascularization.
Older staging systems (e.g., Fontaine, Rutherford) rely almost exclusively on ischemic symptoms and hemodynamics. But two patients with identical ABI can have dramatically different outcomes: one with a small superficial ulcer and no infection may heal with revascularization alone, while another with extensive forefoot gangrene and deep infection may require primary amputation regardless of perfusion.
WIfI captures this heterogeneity. Multiple validation cohorts have shown WIfI stage correlates strongly with both major amputation risk and wound-healing time, and — critically — helps identify patients whose wounds are unlikely to benefit from revascularization at all (very low wound burden with adequate perfusion, or overwhelming tissue loss where salvage is not feasible), sharpening the selection of candidates for aggressive limb-salvage intervention.
Once WIfI stage confirms revascularization is indicated, angiography (CTA, MRA, or catheter-based) defines exactly where disease lies along the arterial tree — inflow (aortoiliac, common/superficial femoral) versus outflow (popliteal, tibial, pedal) — and how many vessels remain patent down to the foot. This anatomic pattern, not ischemia severity alone, largely dictates whether endovascular therapy is technically feasible and which bypass target is optimal if surgery is chosen.
Inflow disease affects the aorta, iliac arteries, and common femoral artery — segments that, when diseased, reduce the pressure head delivered to the entire limb. Inflow lesions are often the most straightforward to treat endovascularly (iliac stenting has excellent long-term patency) and are typically addressed first, since correcting inflow alone can sometimes improve perfusion enough to permit wound healing or to improve the target for a subsequent distal procedure.
Outflow (infrainguinal) disease — femoropopliteal and infrapopliteal (tibial) — is more common in CLTI, particularly in patients with diabetes mellitus and end-stage renal disease, where disease is characteristically diffuse, heavily calcified, and concentrated in the below-knee tibial vessels while sparing the pedal arch. This distribution pattern has direct implications: heavily calcified, long-segment tibial occlusions are far less amenable to durable endovascular repair than focal femoropopliteal lesions.
Three paired tibial vessels — the anterior tibial, posterior tibial, and peroneal arteries — carry blood from the popliteal artery to the foot via the pedal and plantar arches. "Runoff" refers to how many of these vessels remain patent in continuity to the foot.
Zero-vessel runoff (all three occluded) represents the most severe outflow-limited state and predicts poor bypass graft patency and high failure rates for any single distal intervention — direct in-line flow to the wound-bearing angiosome becomes the priority. One-vessel runoff may be adequate if it is in direct angiosomal continuity with the wound. Two- to three-vessel runoff generally provides the most durable outcomes for both endovascular and surgical strategies, and offers greater flexibility in target selection.
The Global Limb Anatomic Staging System (GLASS) formalizes this assessment, combining femoropopliteal and infrapopliteal disease grades with runoff status into a single anatomic severity grade (I-III) that, together with WIfI stage and patient risk, feeds the overall revascularization strategy.
A wound perfused by direct in-line flow through a single patent tibial vessel in angiosomal continuity often heals more reliably than one perfused indirectly through collateral flow from two "healthier-looking" but anatomically remote vessels — anatomic targeting matters as much as vessel count.
The foot is divided into distinct angiosomes — three-dimensional vascular territories, each supplied by a specific source artery (e.g., the medial plantar branch of the posterior tibial artery supplies the heel and medial plantar surface; the anterior tibial/dorsalis pedis supplies the dorsum). Direct revascularization — restoring flow through the specific artery supplying the angiosome containing the wound — is associated with faster healing and higher limb salvage rates compared with indirect revascularization relying on collateral perfusion, particularly in diabetic patients with impaired collateral networks.
When the ideal angiosomal target vessel is not reconstructable, indirect revascularization through a well-collateralized adjacent territory remains a reasonable fallback, but expected healing time is typically longer and success less certain.
With WIfI stage and anatomic pattern defined, the multidisciplinary team chooses between an endovascular-first strategy (angioplasty ± stenting) and a bypass-first strategy (open surgical reconstruction with autologous vein or prosthetic conduit). This decision integrates anatomic complexity, conduit availability, and patient surgical risk — a framework substantially clarified by the BEST-CLI randomized trial.
Endovascular therapy — balloon angioplasty, drug-coated balloons, bare-metal or drug-eluting stents, and increasingly atherectomy or specialty crossing devices for chronic total occlusions — offers lower periprocedural morbidity, shorter hospital stay, and the ability to treat multiple levels of disease in a single session under local or regional anesthesia. It is generally favored for focal or moderate-length lesions, good-risk anatomy with maintained runoff, and patients with significant surgical comorbidity (severe cardiac or pulmonary disease, hostile abdomen/groin, limited life expectancy).
Limitations include lower durability in long-segment, heavily calcified, or occluded tibial disease, and the potential need for repeat reintervention as restenosis or re-occlusion occurs over time — an acceptable trade-off in patients for whom durability matters less than avoiding surgical risk.
Open surgical bypass creates a new conduit — ideally the patient's own great saphenous vein (GSV) — from a healthy inflow artery to a target vessel beyond the diseased segment, restoring durable in-line flow. Autologous single-segment GSV bypass remains the most durable infrainguinal reconstruction, with reported patency and limb-salvage rates exceeding most endovascular alternatives at 3-5 years, particularly for long-segment or heavily calcified tibial occlusive disease poorly suited to endovascular repair.
When adequate single-segment vein is unavailable, options include spliced/composite vein, arm vein, or prosthetic (PTFE) conduit — each with progressively lower long-term patency, especially for below-knee targets. Surgical risk (cardiac clearance, wound-healing capacity, frailty) must be weighed against these durability advantages, since bypass carries greater periprocedural morbidity than endovascular intervention.
BEST-CLI (2023) found that among patients with an adequate single-segment great saphenous vein, bypass-first resulted in significantly fewer major adverse limb events than endovascular-first therapy — but among patients without usable vein, outcomes between the two strategies were statistically similar, reframing conduit availability as a central branch point in the decision algorithm.
1. Confirm the diagnosis — establish CLTI with objective hemodynamic testing and stage severity with WIfI. 2. Assess urgency — active infection or extensive gangrene may require debridement/drainage or amputation of non-salvageable tissue before or alongside revascularization. 3. Map anatomy — CTA/MRA or catheter angiography defines inflow and outflow disease pattern and runoff (GLASS grade). 4. Assess conduit — duplex-map the great saphenous vein for adequate diameter and length. 5. Assess surgical risk — cardiac, pulmonary, renal, and functional status determine bypass candidacy. 6. Apply the matrix — good vein + long-segment/occluded tibial disease + acceptable surgical risk favors bypass-first; poor vein, high surgical risk, or focal endovascular-favorable anatomy favors endovascular-first. 7. Reassess after intervention — if the first strategy fails to restore adequate perfusion or the wound fails to progress, escalate to the alternative strategy without delay.
Whichever strategy is chosen, the physiologic goal is identical: convert a foot receiving inadequate, often collateral-dependent flow into one receiving direct, pulsatile, in-line arterial perfusion sufficient to support the metabolic demands of wound healing, infection clearance, and tissue viability.
Technical success — a patent lumen on completion angiography or a functioning bypass graft — is necessary but not sufficient. The clinically meaningful endpoint is hemodynamic success: restoration of ankle and toe pressures, TcPO2, or skin perfusion pressure above thresholds empirically associated with wound healing. Even a technically perfect angioplasty that fails to raise toe pressure above roughly 30 mmHg (higher in diabetics or dialysis patients, whose microvascular disease independently impairs healing) is unlikely to salvage a wound.
Pulsatile flow also matters biologically beyond raw pressure: pulsatile shear stress supports endothelial function, nitric oxide signaling, and angiogenesis at the wound bed — properties that static or collateral-dependent flow does not replicate as effectively.
Once adequate perfusion is restored, the wound-healing cascade can proceed: hemostasis and inflammation give way to a proliferative phase requiring oxygen-dependent collagen synthesis and angiogenesis, followed by remodeling. Chronic ischemia arrests wounds in a prolonged inflammatory phase — restoring flow is what allows the biology to move forward.
Adjunctive measures after revascularization are frequently essential: sharp debridement of non-viable tissue, offloading (particularly for diabetic plantar ulcers), infection control with targeted antibiotics, and glycemic optimization. Revascularization creates the physiologic opportunity for healing; it does not by itself heal the wound.
Reperfusion is a necessary precondition, not a guarantee — surveillance duplex ultrasound and clinical wound assessment at regular intervals are required to detect restenosis or graft failure before it silently reverses the perfusion gain.
Optimal CLTI outcomes are consistently associated with a coordinated, multidisciplinary "toe-and-flow" model bringing together vascular surgery/interventional radiology (revascularization), podiatry (debridement, offloading, biomechanics), infectious disease (targeted antimicrobial therapy), endocrinology (glycemic control), and wound care nursing (dressing selection, adjunctive therapies such as negative-pressure wound therapy). Programs organized around this model report meaningfully lower major amputation rates than fragmented, single-specialty care pathways, underscoring that revascularization is one essential component of a larger limb-preservation system rather than a stand-alone cure.
The final measure of success is longitudinal: does the wound heal, does the limb remain intact, and is that outcome durable. Healing probability and amputation risk evolve together over weeks to months after revascularization, shaped by technical durability, wound severity at baseline (WIfI), and ongoing control of risk factors.
After revascularization, healing and amputation risk trend in opposite directions but on the same clock. Wounds that show measurable area reduction by 4 weeks are statistically likely to go on to heal; wounds that stall or progress despite adequate perfusion should trigger prompt reassessment for infection, graft/stent failure, inadequate offloading, or unaddressed comorbidity. High baseline WIfI stage (extensive tissue loss, severe ischemia, or deep infection) predicts both slower healing and higher amputation risk even after technically successful revascularization — perfusion restoration narrows but does not eliminate that gap.
Both bypass grafts and endovascular repairs are subject to failure over time — vein graft stenosis from intimal hyperplasia, stent restenosis, or recurrent atherosclerotic progression. Structured surveillance (serial duplex ultrasound, ankle-brachial indices, clinical wound checks) enables detection of failing — but not yet failed — reconstructions, when secondary intervention (angioplasty of a vein graft stenosis, revision bypass) is far more likely to preserve the limb than intervention after complete occlusion has already occurred.
Roughly one in three to four patients with CLTI will require a secondary procedure within the first year to maintain patency — surveillance, not a single successful procedure, is what ultimately protects the limb.
Long-term limb and patient survival after revascularization depend heavily on secondary prevention: smoking cessation, glycemic control in diabetes, statin and antiplatelet therapy, blood pressure management, and structured foot care to prevent recurrent ulceration. CLTI is a marker of systemic, not just regional, atherosclerotic disease — patients face substantial cardiovascular and cerebrovascular event rates, and five-year mortality after CLTI diagnosis exceeds that of many common cancers. A successful revascularization that restores a functional limb should be paired with the same intensity of medical risk-factor management applied to coronary and cerebrovascular disease, since the arterial pathology is the same disease expressed in a different vascular bed.